Compelling evidence suggests that both myoinositol and D-chiro-inositol (DCI) can counteract downstream consequences of insulin resistance for managing PCOS. On one hand, DCI facilitates insulin activity mainly on non-ovarian tissues, while myoinositol modulates glucose metabolism and FSH-signalling to show specific effects on the ovary. Moreover, myoinositol modulates steroid metabolism through non-insulin-dependent pathways to improve ovarian functions.7 In short, DCI and myoinositol activity involves different biological mechanisms. However, by combining myoinositol and DCI in a ratio corresponding to their physiological plasma relative amount (40:1) both inositol isoforms can be synergistically integrated.

Documented data suggests that optimal combination of 40:1 ratio between myo-inositol and D-chiro-inositol can restore ovulation in PCOS women.8 When combined with Vitamin D, it can further elevate insulin sensitivity and lowers androgen levels.

Conclusion:

Myoinositol: D-chiro-inositol (40:1) treatment can be considered as a first-line treatment to restore ovulation in PCOS women